DS
JAZZ icon

David Shaw’s Jazz Pharmaceuticals JAZZ Stock Holding History

David Shaw’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,400
Closed -$3.04M – 4094
2019
Q4 		$3.04M Buy
+20,400
New +$2.78M ﹤0.01% 2139
2017
Q4 		– Sell
-5,700
Closed -$834K – 3650
2017
Q3 		$834K Hold
5,700
– – ﹤0.01% 2603
2017
Q2 		$886K Buy
+5,700
New +$872K ﹤0.01% 2489
2014
Q3 		– Sell
-2,500
Closed -$368K – 4236
2014
Q2 		$368K Buy
+2,500
New +$347K ﹤0.01% 3728

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

David Shaw's JAZZ Position: Q2 2026 in Review

David Shaw reduced its Jazz Pharmaceuticals (JAZZ) stake by 71% in Q2 2026, selling an estimated $46.2M and leaving 87,075 shares worth $21M. The position accounts for 0.01% of the portfolio, ranked #1260.

David Shaw first reported a position in JAZZ in Q2 2013 and has held it in 41 quarters since. The position peaked at $56.4M in Q1 2026. 640 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • David Shaw held 87,075 shares of Jazz Pharmaceuticals worth $21M as of Q2 2026.
  • David Shaw sold 211,015 Jazz Pharmaceuticals shares in Q2 2026, an estimated $46.2M.
  • Jazz Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1260 holding.
  • David Shaw first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • David Shaw's Jazz Pharmaceuticals position peaked at $56.4M in Q1 2026.
  • 640 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.